Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of immunological changes after subcutaneous immunotherapy with Phleum pratense extract
2005-003460-35Phase 4Completed
- Sponsor
- ALK-Abelló
- Start
- Sep 2005
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, single-arm trial of alutard phleum pratense in allergic rhinoconjunctivitis (ARC), sponsored by ALK-Abelló. Primary endpoint: Change in immediate skin reactivity to Phleum pratense. Started Sep 2005; status: completed.
02
Drugs
alutard phleum pratense
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2005-003460-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003460-35.